Overture Life, the IVF process automation startup has announced a $15M in a Series B round bringing its fundraising total to $37M. Octopus Ventures led the Series B round. Existing investors such as Khosla Ventures, Felicis Ventures, and Marc Benioff also participated in the round. Google Ventures, also participant in the round, made its first Spain-based investment.
Overture Life wants to democratize processes in assisted reproduction to make them more accessible, simplify techniques, and optimize use of resources. Overture currently employs 60 multidisciplinary specialists across the fields of software, microfluidics, robotics, embryology, and reproductive medicine. This round will enable the biotech company to increase its operations in Europe and the US and begin commercialization of its first products.
The company is developing medical devices and novel embryo testing methodologies that will automate all stages of the IVF process, lowering costs and increasing throughput for IVF practitioners. The devices are being developed in its facilities located in Madrid and Barcelona. Overture Life expects to have their first devices available by the end of the current year.
“Overture Life will automate and robotize the embryology lab, improving IVF and egg freezing success rates and lowering costs, thereby democratizing access to fertility,” explains Martin Varsavsky, Overture Life’s CEO, “It is a significant validation of our vision and of our technical progress that investors such as Octopus and GV are joining us in our mission.”
